April 27th 2024
A mobile app may help to expedite treatment and identification for patients with GVHD.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Proton Radiotherapy: The Good, the Bad, and the Uncertain
May 15th 2012Proton radiotherapy is here to stay. Despite the high initial cost, the number of proton therapy machines in the United States and elsewhere is increasing rapidly.[1] The major questions now relate to defining and optimizing their appropriate use.
Identifying Appropriate Patient Groups and Drug Targets in DLBCL
May 15th 2012In their article in this issue of ONCOLOGY, Nastoupil, Rose, and Flowers give a very careful assessment of the options for treating diffuse large B-cell lymphoma (DLBCL), with a focus on the importance of dose density in improving outcomes in this disease.
Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy
This review addresses the rationale and evidence for-and the challenges, cost implications, and future development of-proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
Precision Medicine in the Care of Patients With Leukemia/Lymphoma
May 9th 2012The leukemias and lymphomas represent a group of heterogeneous myeloid or lymphoid clonal stem cell disorders with variable clinical presentation, pathological characteristics, prognosis and recommendations for treatment.[1]
Targeted Therapies in the Management of Leukemia and Lymphoma
May 9th 2012The management of leukemias and lymphomas now includes the use of many targeted therapies. Nurses need to have an understanding of the targeted therapies and their side effects so they can appropriately manage the side effects that their patients with leukemias and lymphomas may experience.
The Golden Era of Genomics and Management of Acute Myeloid Leukemia
April 12th 2012Cancer treatment is undergoing significant developments and entering the new golden era of genomics which has true potentials for the promise of personalized medicine. Large-scale sequencing is changing our understanding of malignant disorders particularly acute myeloid leukemia.
Inotuzumab Ozogamicin Achieves ‘Markedly Long’ Antitumor Response in Indolent B-Cell NHL
April 5th 2012Inotuzumab ozogamicin has achieved a markedly long antitumor response in patients with refractory or relapsed indolent B-cell non-Hodgkin lymphoma (NHL) in an ongoing phase II study. Interim findings were reported by lead investigator Kenneth Luu, PhD, associate director of Pfizer global R&D.
Investigational Smac Mimetic TL32711 Targets Key Lymphoma Mechanism
April 3rd 2012A combination of TL32711, an investigational second mitochondrial-derived activator of caspases (Smac), and tumor necrosis factor-related apoptosis inducing ligand at low concentrations produced marked apoptosis in germinal center lines, with minimal to no effect for each agent alone.
Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.
Mother-To-Be and Cancer Patient-New Treatment Guidelines
February 14th 2012Four publications on cancer treatment during pregnancy were published last week in the journal Lancet, serving as new treatment guidelines for chemotherapy and surgery in pregnant patients with solid tumors and hematologic malignancies.
AL Amyloidosis: New Drugs and Tests, but Old Challenges
February 9th 2012Immunoglobulin light chain (AL) amyloidosis develops in 2% of individuals with monoclonal plasma cell dyscrasias. In this issue of ONCOLOGY, Drs. Gertz and Dispenzieri discuss AL amyloidosis, highlighting progress in the field along with outstanding challenges.
Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma
The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another.
Continuing Good News for Chronic Myeloid Leukemia Patients
January 13th 2012The results of the 2-year follow-up of the dasatinib DASISION phase III trial show the continued superiority of the drug compared to imatinib. The results provide further support for treatment of first-line chronic phase chronic myeloid leukemia patients that harbor the Philadelphia chromosome.
ASH: Two Rituximab Dosing Strategies Come Out on Par
December 14th 2011The phase III randomized RESORT (ECOG Protocol E4402) trial asked whether a maintenance schedule of rituximab every 3 months would lead to a superior disease control outcome compared to retreatment upon progression. The answer, presented this week at ASH, is no.
ASH: Novel BTK Inhibitor PCI-32765 Shows Promise to Change the Paradigm for Treatment of CLL
December 14th 2011Updated findings from a multicenter phase Ib/II clinical trial suggest that the novel Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 may be an important new targeted treatment approach for patients with chronic lymphocytic leukemia.
ASH: Triple Immunotherapy Shows Activity in Lymphoma Metastasized to the Central Nervous System
December 14th 2011Researchers presented a late-breaking abstract reporting activity in a metastatic lymphoma mouse model of two monoclonal antibodies combined with CpG, a short synthetic oligonucleotide agonist of TLR9, that mimic bacterial and viral DNA and facilitates a pro-inflammatory immune response.
ASH: For Unrelated Donor Transplant, Bone Marrow Preferred
December 13th 2011The first plenary session at this year’s ASH was kicked off by the presentation of a study that showed that when stem cells come from donors unrelated to the patient there is no difference in patient survival between the use of cells sourced from peripheral blood or bone marrow.
ASH: Gemtuzumab-A Potential New Use for an Old Drug in AML
December 13th 2011The phase III trial comparing the use of gemtuzumab ozogamicin combined with chemotherapy to chemotherapy alone in newly diagnosed acute myeloid leukemia (AML) patients provides evidence that the combination treatment may be promising in this patient population.